Additional Information
Market: AIM
Sector: General Mining - Nickel and Cobalt
EPIC: AFE
Latest Price: 3.13p  (-3.69% Descending)
52-week High: 11.00p
52-week Low: 2.88p
Market Cap: 21.72M
1 year chart
1 day chart
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
African Eagle Resources
www.africaneagle.co.uk/default.asp

 

African Eagle is a nickel exploration and development company listed on the London AIM (AFE) and Johannesburg AltX (AEA) stock exchanges.

The Company is currently conducting a Bankable Feasibility Study on its flagship asset, the Dutwa Project in Tanzania.

Most recently the Board and management was strengthened for the Company's development and production phase.

 

Pdf

African Eagle Resources: Dutwa project puzzle coming together

27th Jan 2012, 3:45 pm by Giles Gwinnett The appointment of finance expert Don Newport and resource specialist Dr Christopher R. Pointon as non-executives was welcomed by Ocean Equities analyst Christopher Welch, who said it demonstrated the potential quality of the firm's flagship project

African Eagle Resources' (LON:AFE) appointment of two new directors today ends a busy week of activity as it moves its Dutwa nickel project nearer to bankable status.

It had also hired two specialist companies for vital roles in the preparation of a bankable feasibility study (BFS) for the Tanzanian project, due at the end of this year.

The appointment of finance expert Don Newport and resource specialist Dr Christopher R. Pointon as non-executives was welcomed by Ocean Equities analyst Christopher Welch, who said it demonstrated the potential quality of the firm's flagship project.

"The attraction of such high calibre individuals to African Eagle supports our view that Dutwa is one of the best nickel projects in the current development pipeline," he said.

"There has been a marked change in the management team at African Eagle over the last six months, following the appointment of Trevor Moss as the new CEO," he said.

Welch said Newport will be able to assist in financing the construction of Dutwa, while Pointon's steel materials supply and nickel production experience will augment Trevor Moss and Aidan Schoonbee’s African mine project development expertise.

African Eagle has streamlined the BFS so it can be completed within 12 months, while Schoobee will now marshal the feasibility study’s consulting team.

World leading metallurgical and engineering consulting  firms have been engaged. Lycopodium Minerals will be the engineer to complete the (BFS) for Dutwa, while SGS Metallurgy Laboratory will be responsible for the pilot test programme - an essential component of that BFS.

Last week, African Eagle told investors it had selected atmospheric tank leaching as the metallurgical process method for recovering ores at Dutwa after it decided against the heap leaching process.

Welch likened the hiring of Lycopodium, the preeminent EPCM (engineering, procurement, and construction management) contractor in Tanzania, to the last 'big piece of the puzzle' in completing the feasibility study on Dutwa.

And following Wednesday's statement that the SGS laboratory had been chosen to test the Dutwa ores, the Ocean Equities’ analyst said Trevor Moss was now bringing his experience to bear as a mine builder to get the development of Dutwa on track.

"African Eagle’s market cap at just £22m belies the value of the world class nickel asset in its portfolio so we see little downside risk to its share price and expect the share price to rise as the development momentum continues to build," he said.

Analyst Sam Wahab, at broker Seymour Pierce, which rates the stock a 'buy', added that while the recent releases are not in themselves price sensitive, they did prove the company continued to move forward with the development of its 99 million tonnes at 0.93 per cent nickel resource.

The broker targets a price of 20 pence for the stock.

As at 3.45pm, African Eagle shares were trading up 2.33 per cent, at 5.50 pence each.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.